1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
- DOI
- 10.1016/s0140-6736(26)00665-3
- Published
- 2026 Aug 1
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-26-00665-3,
title = {1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.},
author = {Sotomi Y and Kozuma K and Higuchi Y and Nakazawa G and Morino Y and Ando K and Ako J and Tanabe K and Muramatsu T and Kobayashi K and Ichibori Y and Ishihara T and Hirooka K and Suwa S and Warisawa T and Naganuma T and Kikuchi A and Shutta R and Okamoto N and Tanabe Y and Okamura A and Kashiwabara K and Hikoso S and Sakata Y and OPTIMA-AF Investigators},
year = {2026},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(26)00665-3},
url = {https://doi.org/10.1016/s0140-6736(26)00665-3}
}RIS
TY - JOUR TI - 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. AU - Sotomi Y AU - Kozuma K AU - Higuchi Y AU - Nakazawa G AU - Morino Y AU - Ando K AU - Ako J AU - Tanabe K AU - Muramatsu T AU - Kobayashi K AU - Ichibori Y AU - Ishihara T AU - Hirooka K AU - Suwa S AU - Warisawa T AU - Naganuma T AU - Kikuchi A AU - Shutta R AU - Okamoto N AU - Tanabe Y AU - Okamura A AU - Kashiwabara K AU - Hikoso S AU - Sakata Y AU - OPTIMA-AF Investigators PY - 2026 JO - Lancet (London, England) DO - 10.1016/s0140-6736(26)00665-3 UR - https://doi.org/10.1016/s0140-6736(26)00665-3 ER -
APA
Y, S., K, K., Y, H., G, N., Y, M., K, A., J, A., K, T., T, M., K, K., Y, I., T, I., K, H., S, S., T, W., T, N., A, K., R, S., N, O., Y, T., A, O., K, K., S, H., Y, S., & Investigators, O. (2026). 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00665-3
Source records
- pubmed · retrieved 2026-09-26T22:59:44.198Z
- europe-pmc · retrieved 2026-09-26T22:59:44.215Z